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Cancer cells migrate from the primary site to other parts 
of the body and generate metastatic foci, which cause 
death. Therefore, therapy for metastasis prevention is 
required. Given that the enhancement of cell migration 
is necessary for metastasis, inhibition of cancer cell migra-
tion may prevent metastasis.
Basal- like breast cancer cell lines have a high migratory 
ability, and are a useful model for studying metastasis. 
They show an elongated morphology in cell culture. Focal 
adhesion is required for cell migration. In cells having 
an elongated morphology, focal adhesion is observed at 
the front and the rear regions of a cell [1]. At the first 
step of focal adhesion formation, membrane- bound adhe-
sion molecules, called integrins, form a heterodimer of 
alpha and beta subunits [1]. Subsequently, focal adhesion 
molecules, such as focal adhesion kinase and paxillin, are 
recruited to the cytoplasmic tail of integrin molecules 
[2]. This complex is called a nascent adhesion or a focal 
complex [2, 3]. For focal adhesion formation, nascent 
adhesions appear at the leading edge of a cell, and 
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Abstract
A drug for metastasis prevention is necessary. The orally administered anticancer 
drug S- 1 contributes to cancer therapy. In a mouse xenograft model of meta-
static breast cancer from our previous study, the administration of S- 1 inhibited 
lung metastasis. However, the mechanism of inhibition remains elusive. S- 1 
contains 5- chloro- 2,4- dihydroxypyridine (CDHP), which does not have the 
 antigrowth activity, but prevents the degradation of 5- fluorouracil, an anticancer 
reagent. In this study, we found that CDHP treatment shrinks cell morphology 
in metastatic basal- like breast cancer cell lines. Wound healing assays showed 
reduced cell migration in CDHP- treated cells. At the molecular level, CDHP 
treatment reduced the number of nascent adhesions, whereas the number of 
mature focal adhesions was not changed. These findings indicate that CDHP 
impairs focal adhesion formation, which results in a reduction in cell migration. 
For the in vivo metastasis assay, we used a highly lung- metastatic cell line. We 
xenografted them into immunodeficient mice, and administered CDHP. To 
determine whether CDHP prevents metastasis, we measured the weights of har-
vested lungs. The results showed that the lung weights of the CDHP- treated 
animals were not significantly different compared to the no- tumor controls, 
whereas the vehicle group showed a number of metastatic foci and an increase 
in lung weight. These observations indicate that CDHP administration prevents 
metastasis. This study reveals a novel effect of CDHP for lung metastasis pre-
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subsequently, some of them become mature focal adhe-
sions [3]. Vinculin localizes to an adhesion complex, and 
the actin cytoskeleton is organized, bringing about focal 
adhesion maturation [2, 3]. Mature focal adhesions disas-
semble, and new focal adhesions assemble [1, 4]. If focal 
adhesion formation is impaired, cell migration is reduced.
The orally administered fluoropyrimidine, S- 1, is com-
posed of a 1:0.4:1 molecular ratio of tegafur, a masked 
form of 5- fluorourcil: 5- chloro- 2,4- dihydroxypyridine, a 
potent dihydropyrimidine dehydrogenase (DPD) inhibitor 
(CDHP): potassium oxonate, an inhibitor of 5- fluorourcil 
phosphorylation in the gastrointestinal tract [5–7]. Both 
CDHP and potassium oxonate have no antigrowth activ-
ity, whereas 5- fluorourcil inhibits growth. CDHP inhibits 
5- fluorourcil degradation in liver, which results in the 
maintenance of the 5- fluorourcil concentration in the 
body. S- 1 is used for therapies for various cancers, such 
as breast, gastric, and pancreatic cancers [8–12]. The pre-
vious study has reported that S- 1 administration inhibits 
metastasis of a high lung- metastatic subline of a basal- like 
breast cancer cell line, MDA- MB- 231, in a mouse xeno-
graft model [13]. Although 5- fluorourcil inhibits cancer 
growth, how S- 1 prevents metastasis remains elusive. In 
this study, we aimed to reveal the mechanism of anti-
metastatic activity of S- 1. We focused on CDHP, because 
tegafur has antigrowth activity and it is difficult to analyze 
only antimetastatic activity, and potassium oxonate mainly 
localizes in gut after oral administration of S- 1 and does 
not seem to affect the activities of cancer cells generated 
in other organs. Here we show a novel effect of CDHP 
on metastasis prevention. Our findings may contribute 
to the development of future metastasis inhibitors.
Materials and Methods
Cell culture
Basal- like breast cancer cell lines, SUM159 and MDA- 
MB- 231 were obtained from Asterand (Detroit, MI) and 
the American Type Culture Collection (Manassas, VA), 
respectively. MDA- MB- 231 LLM cells were established 
from metastasized MDA- MB- 231 cells [13]. Short tandem 
repeat analyses were performed for cell authentication in 
May 2017, and the results showed no contamination and 
no alteration of SUM159 or MDA- MB- 231 cells. MDA- 
MB- 231 LLM cells were considered to be MDA- MB- 231 
cells. SUM159 cells were maintained with Ham’s F- 12 
nutrient mixture containing 5% FBS, 5 μg/mL insulin, 
1 μg/mL hydrocortisone, and 10 mmol/L HEPES. MDA- 
MB- 231 cells were maintained with RPMI- 1640 containing 
10% FBS. CDHP (Tokyo Chemical Industry, C2243, Tokyo, 
Japan) was dissolved in dimethyl sulfoxide (DMSO). Cells 
were treated with CDHP for 3 days, and analyzed. For 
the wound healing assay, a confluent culture was manu-
ally scratched with a 200 μL tip. For the invasion assay, 
cells were treated with CDHP for 2 days. Twenty thousand 
cells were plated into matrigel- coated boyden chamber, 
and incubated for 24 h. In the wound healing and the 
invasion assays, to inhibit cell proliferation during incuba-
tion, 1 μg/mL of mitomycin C was added. To analyze 
cell migration and invasion, cells were stained with crystal 
violet.
Immunocytochemistry
For immunocytochemistry, cells were plated on a glass- 
bottom chamber slide (Matsunami Glass, SCS- 008, Osaka, 
Japan). After fixation, cells were washed, and permeabilized 
with 0.5% Triton X- 100. Subsequently, cells were washed, 
and incubated with blocking buffer that contained 5% 
goat serum and 1% BSA. After blocking, cells were incu-
bated with the primary antibodies, mouse anti-vimentin 
antibody (Sigma, V6389, St. Louis, MO, 1:20 dilution), 
mouse anti- E- cadherin antibody (BD Biosciences, 610182, 
San Jose, CA, 1:50 dilution), rabbit anti-phospho- paxillin 
antibody (Cell Signaling Technology, 2541, Danvers, MA, 
1:20 dilution) and mouse anti-vinculin antibody (Sigma, 
V9131, 1:200 dilution). Cells were washed, and stained 
with the secondary antibodies, rabbit anti- mouse IgG 
antibody conjugated to Alexa 568 (Life Technologies, 
A11061, Carlsbad, CA, 1:200 dilution), goat anti- rabbit 
IgG antibody conjugated to Alexa Fluor 546 (Life 
Technologies, A11010, 1:1000 dilution) and goat anti- 
mouse IgG conjugated to Alexa Fluor 488 (Life 
Technologies, A11001, 1:1000 dilution). In cells immu-
nostained for vimentin and E- cadherin, nucleus was coun-
terstained with DAPI. Fluorescent images were obtained 
using an all- in- one microscope (Keyence, BZ- 9000, Osaka, 
Japan).
In vivo metastasis assay
All animal study procedures were performed according 
to the protocols and guidelines of the Institutional Animal 
Care and Use Committee of Taiho Pharmaceutical Co., 
Ltd. Ethical approval was obtained prior to the execution 
of animal experimentation. Five- week- old female C.B- 17/
Icr scid/scid mice were purchased from CLEA Japan (Tokyo, 
Japan). All mice were housed under specific pathogen- free 
conditions. A piece of tumor tissue of the MDA- MB- 231 
LLM cells was xenografted into the mammary fat pad. 
The components of S- 1 were synthesized at Taiho 
Pharmaceutical Co., Ltd. Hydroxypropyl methylcellulose 
(vehicle), CDHP or S- 1 was administered orally every 
day. Paclitaxel (Tokyo Chemical Industry, P1632) was 
dissolved in 8.3% Cremophor EL and 8.3% ethanol in 
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saline, and administered intravenously. Tumors at the 
xenografted sites were excised on day 24 under analgesic 
treatment with pentobarbital and meloxicam, and on day 
64 mice were killed and whole lungs were harvested.
Statistical analyses
For the analyses of the adhesion signals, Student’s t- test 
was used. For the wound healing assay, the invasion assay 
Figure 1. 5- Chloro- 2,4- dihydroxypyridine (CDHP) treatment reduces cell migration (A) Images of CDHP- treated cells are shown. Cells were cultured 
with CDHP for 3 days. (B) Wound healing assays were performed to analyze cell migration. Migrated cells are observed in scratched areas at 24 and 
18 h in SUM159 and MDA- MB- 231 cells, respectively. (C) The number of migrated cells were counted (n = 5 scratched areas). Inhibition of migration 
was observed in the cells treated with 1, 10, and 100 μmol/L CDHP. (D) The number of invaded cells were counted (n = 4). Scale bars indicate 100 μm. 
*P < 0.05 compared to DMSO controls (Dunnett’s test).
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and the in vivo experiments, Dunnett’s test was used. 
P < 0.05 was considered statistically significant. Error bars 
indicate standard deviations.
Results and Discussion
CDHP treatment reduces cell migration in 
basal- like breast cancer
Cancer cells migrate from the primary tumor to other 
organs during metastasis. In cell culture, morphological 
changes reflect the alteration of migratory ability. To 
determine whether CDHP alters cell migration, we treated 
the basal- like breast cancer cell lines SUM159 and MDA- 
MB- 231 with CDHP, and observed their morphology. In 
the DMSO control, basal- like breast cancer cells showed 
an elongated morphology, and no remarkable change was 
observed in the cells treated with 0.01 and 0.1 μmol/L 
CDHP (Fig. 1A). In the 1, 10, and 100 μmol/L CDHP 
treatment groups, the cells were shrunken (Fig. 1A), sug-
gesting that CDHP treatment alters cell migration.
To investigate the effect of CDHP treatment on cell 
migration, we performed wound healing assays. In the 
DMSO control, scratched regions were closed after 24 
and 18 h in SUM159 and MDA- MB- 231 cells, respectively 
(Fig. 1B). Cells treated with 1, 10, and 100 μmol/L CDHP 
showed reduced migration, whereas the migration of 0.01 
and 0.1 μmol/L CDHP- treated groups were not significantly 
changed compared to the DMSO control group (Fig. 1B 
and C). In addition, we performed the invasion assays. 
CDHP- treated groups showed reduction in invasion ability 
(Fig. 1D). These results indicate that CDHP treatment 
reduces migration and invasion in basal- like breast cancer 
cells.
For further study, we immunostained cells with anti-
bodies for vimentin, a mesenchymal marker, and 
E- cadherin, an epithelial marker, because alteration of 
mesenchymal and epithelial states changes cell morphol-
ogy. However, we did not observe remarkable alteration 
of vimentin and E- cadherin signals between DMSO control 
and CDHP- treated groups (Fig. 2). This suggests that 
CDHP treatment does not change mesenchymal and epi-
thelial states in basal- like breast cancer cells.
CDHP treatment reduces the number of 
nascent adhesions
In migratory cells, the formation of new focal adhesions 
moves a cell forward. Therefore we hypothesized that 
CDHP affects focal adhesion formation. During focal 
adhesion formation, paxillin localizes adhesion complexes 
from the stage of nascent adhesion formation to focal 
adhesion maturation, whereas vinculin localizes adhesion 
complexes at the stage of focal adhesion maturation [2]. 
In an adhesion complex, paxillin is phosphorylated by 
focal adhesion kinase [14].
To analyze the effect of CDHP on focal adhesion for-
mation, we performed immunostaining with antibodies 
for phosphorylated paxillin (phospho- paxillin) and for 
vinculin. Focal adhesion signals are observed as dots at 
the edge region of a cell. A single- positive immunostain-
ing signal of phospho- paxillin indicates nascent adhesion, 
and a double- positive phospho- paxillin/vinculin signal 
indicates mature focal adhesion. In our staining, the DMSO 
control cells showed phospho- paxillin single- positive and 
phospho- paxillin/vinculin double- positive adhesion signals 
(Fig. 3A). In the cells of CDHP- treated groups, the number 
of phospho- paxillin single- positive signals was reduced, 
Figure 2. 5- Chloro- 2,4- dihydroxypyridine treatment does not change the expression of mesenchymal and epithelial markers Immunostaining images 
of vimentin, a mesenchymal marker, and E- cadherin, an epithelial marker, are shown. MDA- MB- 231 LLM cells were used. Nucleus was counterstained 
with DAPI. Scale bar indicates 200 μm.
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suggesting that CDHP affects focal adhesion formation 
(Fig. 3A).
When counting the number of signals per cell, the 
number of vinculin- positive signals was not affected by 
CDHP treatment (Fig. 3B). The total adhesion number 
was determined by counting the number of phospho- 
paxillin signals, and this number was reduced by CDHP 
treatment (Fig. 3C). The ratio of phospho- paxillin single- 
positive signals was significantly reduced (Fig. 3D). These 
data indicate that CDHP treatment reduces the number 
of nascent adhesions. Our results showed that CDHP 
treatment impairs focal adhesion formation, which may 
result in a reduction in cell migration.
CDHP treatment inhibits lung metastasis
To analyze the effect of CDHP on metastasis in vivo, we 
used a highly lung- metastatic subline of MDA- MB- 231, 
named MDA- MB- 231 LLM [13]. Tumor tissue of the xeno-
grafted site was excised on day 24. On day 64, lungs were 
harvested, and whole lung weight was measured to evaluate 
metastasis. Lung weight on day 64 reflects the frequency 
of metastasis that occurred from day 0 to day 24 (Fig. 4A). 
No obvious metastasis in other organs was observed.
We used 0.5% hydroxypropyl methylcellulose as the vehicle 
control with the concentration of 10 mL/kg. CDHP was 
administered with a final dosage of 2.9 mg/kg, which 
Figure 3. 5- Chloro- 2,4- dihydroxypyridine (CDHP) treatment reduces the number of nascent adhesions (A) Images of double immunostaining for 
phospho- paxillin and vinculin are shown. Cells were cultured with 2 μmol/L CDHP for 3 days. Phospho- paxillin/vinculin double- positive focal adhesions 
have white signals in overlaid images. Yellow arrowheads indicate phospho- paxillin positive, vinculin negative signals. (B–D) The numbers of vinculin- 
positive adhesions (B) and total adhesions (C) were counted. The ratio of phospho- paxillin single- positive adhesions to total adhesions was calculated 
(D). SUM159 cells treated without or with CDHP (n = 32 and 41, respectively) and MDA- MB- 231 cells treated without or with CDHP (n = 40 and 37, 
respectively) were analyzed. Scale bars indicate 10 μm. * and ** indicate P < 0.05 and P < 0.01, respectively, compared to DMSO controls (Student’s 
t- test).
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corresponds to the amount of CDHP in the mice that were 
administered 10 mg/kg of S- 1. In addition, we used CDHP 
at 29 mg/kg, which is the concentration at which no weight 
loss was observed. Ten mg/kg S- 1 and 26.7 mg/kg paclitaxel 
were used as positive controls. Vehicle, CDHP or S- 1 was 
administered every day from day 1 to day 23. Paclitaxel 
was administered on days 29, 36, 44, and 51 to control 
the reduction in metastatic foci by drug administration. No 
body weight loss was observed in any group on day 24.
There was no significant difference in the weights of 
the tumors from the xenografted sites between the vehicle 
and CDHP- treated groups (1.322 g ± 0.580, n = 8 in 
vehicle, 1.443 g ± 0.848, n = 8, P > 0.05 vs. vehicle in 
CDHP 2.9 mg/kg, and 1.304 g ± 0.738, n = 4, P > 0.05 
vs. vehicle in CDHP 29 mg/kg). In the lung tissue, there 
were metastatic foci in the vehicle control, and reduced 
lung metastasis was observed in the CDHP- administered 
group (Fig. 4B). However, in our observation, CDHP treat-
ment did not completely prevent lung metastasis of MDA- 
MB- 231 LLM cells, and lung metastasis was observed in 
all mice administered 2.9 and 29 mg/kg CDHP. Due to 
the generation of metastatic foci, the lung weight of the 
vehicle group was increased compared to the no- tumor 
group (Fig. 4C). CDHP administration inhibited increase 
in lung weight compared to vehicle control, and the lung 
weights of the CDHP- administered groups were not sig-
nificantly increased compared to no- tumor group (Fig. 4C), 
indicating that lung metastasis was suppressed by CDHP.
In this study, we discovered the new effect of CDHP 
for lung metastasis prevention in basal- like breast cancer. 
Figure 4. 5- Chloro- 2,4- dihydroxypyridine inhibits lung metastasis (A) The design of the in vivo metastasis assay is depicted. (B) H&E staining of 
harvested lungs is shown. Metastatic foci were observed in the vehicle control (arrowheads). (C) Lungs weights are graphed. The weight of each lung 
is plotted, and the red bars indicate the mean value of each group. Scale bar indicates 1 mm. ***P < 0.001 compared to no- tumor controls (Dunnett’s 
test). ††P < 0.01, †††P < 0.001 compared to vehicle control (Dunnett’s test).
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In our in vitro experiments, the effect of CDHP was 
moderate. However, we observed remarkable inhibition 
of lung metastasis in CDHP- administered mice. Given 
that in vivo experiments have more severe condition than 
in vitro, cells in in vivo seem to be more sensitive to the 
inhibitory effect of CDHP than in vitro.
CDHP is an inhibitor of DPD [15]. A previous study 
has reported that DPD knockdown impairs the epithelial- 
to- mesenchymal transition in a normal breast epithelial 
cell line [16]. However, in our observations, CDHP did 
not induce epithelial marker expression in basal- like breast 
cancer cell lines (Fig. 2). This suggests that although DPD 
inhibition prevents mesenchymal transition of epithelial 
cells, it cannot induce epithelial transition in breast cancer 
cells that have mesenchymal features.
Conclusions
S- 1 that contains CDHP is not only used in therapies for 
breast cancer, but also for other types of cancer. In clinical 
studies, S- 1 administration for adjuvant chemotherapy is 
effective in gastric and pancreatic cancers [9, 11], although 
a study for breast cancer is ongoing (UMIN000003969). 
These studies suggest that CDHP treatment is useful for 
lung metastasis prevention in various types of cancers. This 
study may contribute to the establishment of novel thera-
peutic approaches using CDHP, and to the development 
of future anticancer drugs for lung metastasis prevention.
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